PRESSRELEASES
19 February, 2025
Nanexa publishes year-end report and Q4 report 2024
The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025.
READ MORE14 February, 2025
Nomination Committee for the 2025 Annual General Meeting in Nanexa AB (publ)
The Nomination Committee for the Annual General Meeting 2025 in Nanexa AB (publ) has been appointed.
READ MORELATEST REPORTS
PRESENTATIONS
2025-02-19
Q4 report commentary with CEO David Westberg and Chairman of the board Göran Ando
2024-11-28
Stora Aktiedagarna Stockholm 28 november
2024-11-25
Phase I study for NEX-22 result presentation and Q&A
MEET NANEXA
Inga planerade träffar
